Skip to main content

Articles By Richard Conway, MBBChBAO, PhD

ice cubes

Topical therapies take centre stage

By Richard Conway, MBBChBAO, PhD
04 June 2022

Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium. 

Read Article
RA.Ow02.jpg

A Big Leap in Modulating Rheumatoid Disease

By Richard Conway, MBBChBAO, PhD
01 June 2022

Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. It is well known that seropositivity for rheumatoid factor and antibodies to cyclic citrullinated peptides (ACPA) can precede RA disease by many years. Many, but by no means all, patients also seem to go through a pre-RA arthalgia phase of varying duration characterised by the presence of increasing joint pain without frank arthritis.

Read Article
GCA temporal artery

Giant Cell Arteritis Novel Treatment Options

By Richard Conway, MBBChBAO, PhD
29 November 2021

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

Read Article
bathroom scale

The Influence of Obesity on Choice of Biologic in Rheumatoid Arthritis

By Richard Conway, MBBChBAO, PhD
23 November 2021

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.

Read Article
PsA.Hands_.jpg

The Need for Comparative Treatment Trials in Psoriatic Arthritis

By Richard Conway, MBBChBAO, PhD
09 November 2021

Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.

Read Article
bathroom scale

The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis

By Richard Conway, MBBChBAO, PhD
07 November 2021

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.

Read Article
GCA temporal artery

Novel treatment options for Giant Cell Arteritis

By Richard Conway, MBBChBAO, PhD
06 November 2021

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

Read Article
Lungs ILD

RA ILD: Stepping out of the shadows

By Richard Conway, MBBChBAO, PhD
09 June 2021

Despite being relatively common and frequently severe, RA-ILD has been a neglected area of research and indeed of clinical management in RA. In recent years we finally seem to have started making some progress in this area and this momentum has continued with a several interesting abstracts at EULAR 2021. Here are four selected for review.

Read Article
CV,risk,MI,heart,cardiac

Turning the Corner on CV Risk in Rheumatoid Arthritis

By Richard Conway, MBBChBAO, PhD
03 June 2021

Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.

Read Article
pills-384846_640%20%281%29.jpg

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

By Richard Conway, MBBChBAO, PhD
30 November 2020

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.

Read Article
×